Fundraising Fox
Mondegobio
Cantanhede, PT · 4 employees on LinkedIn · 1 known investors
Find your way into Mondegobio
Sign up to see every warm intro you have to Mondegobio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Mondegobio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Mondego Bio develops PTPN2 (protein tyrosine phosphatase non-receptor type 2) inhibitors as immuno-oncology therapies, aiming to enhance IFNγ signaling to make tumor cells more susceptible to immune attack. The company focuses on small-molecule cancer immunotherapy drug candidates with oral bioavailability and improved safety profiles.
Investors · 1
OrbiMedlisted by OrbiMedNew York · $1M – $75M
How we know: OrbiMed's portfolio page · the VCSheet dataset · Not right? Tell us
Frequently asked questions
- What does Mondegobio do?
- Mondego Bio develops PTPN2 (protein tyrosine phosphatase non-receptor type 2) inhibitors as immuno-oncology therapies, aiming to enhance IFNγ signaling to make tumor cells more susceptible to immune attack. The company focuses on small-molecule cancer immunotherapy drug candidates with oral bioavailability and improved safety profiles.
- Who are Mondegobio's investors?
- Mondegobio's investors include OrbiMed.
- Where is Mondegobio headquartered?
- Mondegobio is headquartered in Cantanhede, PT.